Why the study?
Despite evidence supporting sacubitril/valsartan for mortality reduction in heart failure, it remains underprescribed, prompting evaluation of treatment eligibility in a Veterans Administration healthcare system.
Sacubitril/valsartan is significantly underprescribed in eligible HFrEF patients within the VA healthcare system, indicating a major gap in optimizing guideline-directed heart failure therapy.
Low uptake despite eligibility in VA HFrEF patients warrants caution on barriers; leaves open implementation gaps and outcome impact.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Han et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: